Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)

NCT05650411 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

828

Enrollment

OTHER

Sponsor class

Conditions

Left Main Coronary Artery Stenosis

Interventions

DEVICE: LMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India).
DRUG: P2Y12 inhibitor-based SAPT after short DAPT
DRUG: Conventional DAPT

Sponsor

IGLESIAS Juan Fernando

Collaborators

[object Object]